Investors

News & Releases

January 7th, 2021

ImmunoPrecise Antibodies Announces Grant of Stock Options

VICTORIA, BC, January 6, 2021 – IMMUNOPRECISE ANTIBODIES LTD. (“IPA” or the “Company”) (NASDAQ: IPA) (TSXV: IPA), a leader in full-service, therapeutic antibody discovery, today announced that its board…

January 6th, 2021

ImmunoPrecise Antibodies to Participate in January Conferences

VICTORIA, British Columbia, January 6 2021 / – IMMUNOPRECISE ANTIBODIES LTD. (“IPA”) (Nasdaq: IPA) (TSXV: IPA) a leader in full-service, therapeutic antibody discovery, today announced that Dr. Jennifer Bath,…

December 30th, 2020

ImmunoPrecise Partners on Launch of SARS-CoV-2 Nanomedicine Therapy Program

Innovative, novel approach to treat and protect against SARS-CoV-2 using thermoresponsive virus-targeting nanoparticles as an inhalation medicine Program includes development of a heat-sensitive fluorescent SARS-CoV-2 detection assay through patient…

December 23rd, 2020

ImmunoPrecise Antibodies to Begin Trading on Nasdaq Stock Exchange

VICTORIA, December 23, 2020 – IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (TSXV: IPA) (Nasdaq Global Markets: IPA), a leader in full-service, therapeutic antibody discovery and development, is pleased…